Trending...
- The 2025 ESPY Awards After Party- Presented by Poppi & High Noon
- General Auction Company Announces August 8th Auction- Now Accepting Consignments
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
SAN JOSE, Calif. - Californer -- Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921 is a small molecule drug available in oral formulation.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
- Laube Titanium to Attend MADE Bike Show in Portland, Oregon
- A Century of Compassion: Butte Humane Society Hosts 114th Anniversary Gilded Garden Gala
- United Set to Hire More Special Olympics Athletes As Customer Service Ambassadors
- Exelon Leader Tamla Olivier Named 2025 Technologist of the Year by Waves of Change STEM Conference
- KIDZ BOP RELEASES BRAND NEW ALBUM 'KIDZ BOP 51' FEATURING HITS "APT" & "PINK PONY CLUB"
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
Source: Biomed Industries Inc.
Filed Under: Medical
0 Comments
Latest on The Californer
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- City of Long Beach to Celebrate Completion of MacArthur Park Rehabilitation Project
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- California: ICYMI: 287,000 jobs and $55 billion in economic growth on the line with key climate program's extension
- Rent Like A Champion Acquires CollegeWeekends
- WNBA Rising Star Jacy Sheldon Makes History with HOLO's First-Ever WNBA Signature Sneaker
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- City of Long Beach to Celebrate Improvements at El Dorado Park
- Club Offers Released on July 17, 2025
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- Up Hill Concierge Launches Curated LA Hospitality for FIFA 2026, Super Bowl, NBA All-Star & LA28
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- Vaulted Deep Signs Deal with Microsoft to Remove Carbon via Waste Management Infrastructure
- The Recording Academy Extends Invitation to The World's No.1 Superstar™—But He's Not Chasing the Award
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- California: Governor Newsom responds to Trump's latest gift to China: Defunding America's only high-speed rail
- California: Governor Newsom announces appointments 7.16.25
- California: Governor Newsom calls on Trump to end Los Angeles militarization, shares community resources